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Abstract
Introduction The biological factors responsible for differ-
ential chemoresponsiveness in oligodendroglial tumours
with or without the −1p/−19q genotype are unknown, but
tumour vascularity may contribute. We aimed to determine
whether dynamic susceptibility contrast (DSC) magnetic
resonance imaging (MRI) could distinguish molecular
subtypes of oligodendroglial tumour, and examined the
relationship between relative cerebral blood volume (rCBV)
and outcome following procarbazine, lomustine and vin-
cristine (PCV) chemotherapy.
Methods Pretherapy rCBV was calculated and inter- and
intraobserver variability assessed. Allelic imbalance in
1p36, 19q13, 17p13, 10p12–15, and 10q22–26 and p53
mutation (exons 5–8) were determined. rCBV was com-
pared with genotype and clinicopathological characteristics
(n=37) and outcome following PCV chemotherapy (n=33).
Results 1p/19q loss was seen in 6/9 grade II oligodendro-
gliomas, 6/14 grade II oligoastrocytomas, 4/4 grade III
oligodendrogliomas, and 3/10 grade III oligoastrocytomas.
rCBV measurements had good inter- and intraobserver
variability, but did not distinguish histology subtype or
grade. Tumours with 1p/19q loss had higher rCBV values
(Student’s t-test P=0.001). Receiver operating characteristic
analysis revealed a cut-off of 1.59 for identifying genotype
(sensitivity 92%, specificity 76%). Tumours with high and
low rCBV showed response to chemotherapy. The −1p/
−19q genotype, but not rCBV, was strongly associated with
response, progression-free and overall survival following
PCV chemotherapy. Tumours with high rCBV and intact
1p/19q were associated with shorter progression-free and
overall patient survival than those with intact 1p/19q and
low rCBV or high rCBV and 1p/19q loss.
Conclusion rCBV identifies oligodendroglial tumours with
1p/19q loss, but does not predict chemosensitivity. The
prognostic significance of rCBV may differ in oligoden-
droglial tumours with or without the −1p/−19q genotype.
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Introduction
Oligodendroglial tumours with combined loss of chromo-
somes 1p and 19q have a more indolent clinical evolution,
respond more favourably to chemotherapy and show
prolonged survival compared to those with intact 1p/19q,
but the basis of these clinical differences is not well
understood [1–5]. In addition, up to 30% of oligodendrog-
lial neoplasms with intact 1p/19q may respond to chemo-
therapy [3, 6, 7], but the genetic and biological factors
associated with response are unknown and not all patients
with oligodendroglial tumours derive durable benefit from
therapy. Assessment of the clinical utility of biological
markers and non-invasive imaging techniques is essential to
advance the clinical management of these patients.
Recently dynamic susceptibility contrast magnetic reso-
nance imaging (DSC-MRI) has been used to calculate
perfusion parameters in gliomas [8, 9], guide biopsy [10],
provide prognostic information [11] and demonstrate differ-
ences in the vascularity of low-grade astrocytomas com-
pared with oligodendrogliomas [8]. It has been suggested
that increased vascularity and concomitant improved drug
delivery may contribute to the chemoresponsiveness of
oligodendroglial tumours, especially as lipophilic drugs
(procarbazine, lomustine and temozolomide), which easily
cross the blood–brain barrier, are used in the treatment of
oligodendrogliomas [12–14]. Currently DSC-MRI is used
in the radiological evaluation of gliomas, but its role in
oligodendroglial neoplasms classified by genotype and the
relationship with response and outcome following chemo-
therapy has not so far been investigated.
The aim of this study was to determine whether DSC-
MRI obtained through routine pre-therapy MR diagnostic
examinations may be used to distinguish molecular sub-
types of oligodendroglial tumours, and to investigate the
influence of tumour blood volume on outcome following
procarbazine, lomustine and vincristine (PCV) chemother-
apy compared to molecular genetics.
Methods
Patient selection
Patients for investigation were selected from those participat-
ing in a prospective study of adult oligodendroglial tumours
eligible forchemotherapyat the Walton Centre forNeurology
and Neurosurgery/Clatterbridge Centre for Oncology be-
tween May 2000 and June 2003 [7, 15–18]. The study had
full ethical approval. For inclusion in this study, patients had
to have (1) given research consent, (2) a histological
diagnosis of oligodendroglioma or oligoastrocytoma based
on the current World Health Organisation (WHO) classifi-
cation [19], (3) a known 1p/19q status, and (4) undergone
DSC-MRI before or after biopsy (2 image-guided; 35 serial
stereotactic), but prior to commencing therapy. All patients
(with primary and recurrent disease) underwent biopsy prior
to PCV. Patients with post-resection imaging were excluded.
DCS-MRI
Imaging studies were obtained using a 1.5-T Signa MR
scanner (General Electric Medical Systems). The MR
imaging protocol consisted of T1-weighted spin-echo (SE)
sagittal sections (400/14 TR/TE), axial fluid attenuated
inversion recovery (FLAIR 8802/142/2200 TR/TE/TI),
axial fast spin-echo (FSE) T2-weighted imaging (4360/102
TR/TE), 2D dynamic susceptibility-weighted, SE, echopla-
nar imaging (EPI 1900/80 ms, bandwidth 62.5) and
postcontrast T1-weighted SE (600/14 TR/TE) or FLAIR
(2280/11/750 TR/TE/TI) axial imaging. The T2-weighted
FLAIR, FSE and postcontrast T1-weighted images were
used to define regions of T2 hyperintensity and T1
enhancement. For the dynamic EPI series, the tumour size
and location, and the position of the margins were
determined from the T2-weighted FLAIR or FSE images
to equally define low-grade and high-grade tumours. Nine
slices were selected to cover the majority of the tumour
volume. Slice thickness was 7 mm, with no gap. A standard
dose of 0.1 mmol/kg body weight of dimeglumine
gadopentetate (Gd DTPA) was injected intravenously
manually at an approximate rate of 3 ml/s. A series of
T2*-weighted multislice image sets (field of view 30×30,
matrix 192×128) were acquired every 2 s during the first
pass of the contrast agent. Image postprocessing was
performed using commercial software (Functool2, version
6.0; Sun Microsystems). Negative enhancement integral
(NEI) maps were generated for each patient relative to the
signal intensity in the superior sagittal sinus (Fig. 1). The
axial slice with the greatest cerebral blood volume and
tumour area was chosen for analysis.
TheradiologicaltumourmarginwasdelineatedontheT2*
sequence axial image using a nongeometric region of interest
(ROI), and a single circular region was placed over normal
brain mirrored in thecontralateralhemisphere.Depending on
tumour location, the mirrored area could include both white
and grey matter. ROIs were placed according to published
methods giving the lowest inter- and intraobserver variability
[20] within the delineated tumour region. Briefly, five ROIs
(area range 12–27 mm
2) were placed over the tumour areas
with the highest blood volume. Cystic and hemorrhagic
regions were avoided and care was taken not to place ROIs
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independent analyses were performed by a neuroradiologist
(T.S.S.) and a neurosurgeon (M.D.J.) blinded to histology and
genotype, to assess inter- and intraobserver variability. For
each observation, data were expressed relative to the internal
reference (four ROIs placed within the delineated mirrored
region of normal brain without deliberate bias towards either
grey or white matter) to generate relative cerebral blood
volume (rCBV) values (mean ROItumour/mean ROInormal brain)
and accommodate physiological differences between patients
[21]. For comparison with clinical data, the mean rCBV from
these three data sets was used.
Molecular genetics
For each patient regions of tumour histology in pretherapy
biopsy specimens (formalin-fixed, paraffin-embedded
tissues or intraoperative diagnostic smear preparations)
representative of the most aggressive tissue available and
the overall pathology diagnosis were selected for laser
capture microdissection to enrich the tumour component in
the samples for analysis. Allelic imbalance was investigated
using paired normal (microdissected uninvolved brain or
DNA from blood) and tumour tissue samples and multiple
simultaneous PCR amplification of a panel of microsatellite
Fig. 1 Calculation of rCBV using DSC-MR. CBV is derived from the
drop in the T2* signal after injection of a bolus of paramagnetic
compound [8, 9]. Using Functool2, the radiological tumour margin
was delineated on the T2* sequence axial image and a single circular
ROI placed over normal brain mirrored in the contralateral hemisphere
(a, b). Negative enhancement integral (NEI) colour maps were
generated (c, d) relative to the signal intensity in the superior sagittal
sinus using image data between dynamic scans immediately before
and after the contrast transient. CBV is proportional to the area under
the contrast agent concentration-time curve and was calculated for
each ROI by Functool2 using algorithms to integrate ΔR2i values
(where ΔR2 is the change in the reciprocal of T2*). rCBV for each
tumour was calculated from signal intensity time curves for individual
ROIs placed within the delineated tumour region or in the large ROI in
the contralateral hemisphere (as illustrated in e and f, arrows scans
adjacent to the contrast transient) as described in the Materials and
methods. a, c, e Low rCBV (0.73±0.17, mean±SD) in a grade II
oligoastrocytoma with intact chromosomes 1p and 19q and; b, d, f
high rCBV (4.15±0.87) in a grade II oligoastrocytoma with the −1p/
−19q genotype
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described previously [16–18]. The microsatellite panel
included: chromosome 1 – D1S2667, D1S508, D1S214
(1p36); chromosome 19 – D19S412, D19S112, D19S596
(19q13); chromosome 17 – D17S796, D17S1176,
D17S1353 (17p13); chromosome 10p – D10S89,
D10S179 (10p12-10p15); chromosome 10q – D10S1687,
D10s2491, D10S583, D10S587, D10S212 (10q22-10q26).
Additional markers, D1S468, D1S2795 (1p36) and
D19S217, D19S572 (19q13) were used in cases that lacked
informativity for given loci. p53 mutations (exons 5–8)
were detected by direct sequence analysis of PCR products.
PCV chemotherapy, response and clinical outcome
All patients receiving oncology therapy had evidence of
advancing disease (either radiographic or clinical progres-
sion) prior to therapy. Patients with mass effect or evidence
of malignancy were treated at presentation; others were
followed clinically until progression. Oncology therapy was
based on individual patient’s clinical status/choice. Patients
fit for PCV were offered PCV chemotherapy, or radiother-
apy if fertility was an issue. PCV chemotherapy was
administered according to standard clinical protocols [22]:
lomustine (CCNU) (110 mg/m
2), procarbazine (60 mg/m
2)
and vincristine (1.4 mg/m
2, maximum 2 mg) were given on
days 1, 8–21, and 8 and 29. respectively. Cycles were
repeated every 6 weeks for a maximum of six cycles. As
described previously [18], a consultant neuroradiologist
reviewed all available MR or CT images taken before,
during and after chemotherapy, and at follow-up. The largest
perpendicular diameters of the tumour were measured on
axial sections of T2-weighted MR images or contrast-
enhanced regions on T1-weighted MR or CT images.
Response was assessed using the criteria of Macdonald et
al. [23] and postcontrast T1-weighted MRI in 25enhancing
tumours. In tumours showing no enhancement (n=6) or in
those in which contrast enhancement was not assessable
(n=1), response was based on T2-weighted images.
Information regarding current management, follow-up and
outcome was collected prospectively. Progression-free sur-
vival(PFS)andoverallsurvival(OS)werecalculatedfromthe
start of PCV to progression, last seen, or death as appropriate.
Statistical analysis
Inter- and intraobserver variability was determined using
Bland and Altman plots [24]. Differences in rCBV between
genetic and clinical factors were assessed using Student’s t-
test for numerical data and the Chi-squared or Fisher’s
exact test for categorical data. Receiver operator character-
istics (ROC) analysis was performed to define the optimal
rCBV cut-off for predicting 1p/19q status. Kaplan-Meier
survival curves were obtained and differences in OS or PFS
were tested for statistical significance using the Log Rank
test. Cox regression multivariate analysis of factors shown
to be significant in univariate analysis was by forward
stepwise entry of parameters at a significance of 0.05 for
entry and 0.01 for removal. Probability (P) values less than
0.05 were considered significant.
Results
The study included 30 patients with primary tumours
without previous therapy and 7 with recurrent or persistent
disease following radiotherapy. Median time between previ-
ous radiotherapy and MR imaging was 6.5 years (range 1.1–
14.2 years). Median age was 44 years (range 28–71 years).
Fig. 2 Bland and Altman plots illustrating interobserver (a, b)a n d
intraobserver (c) variation of rCBV measurements. The greatest variation
is seen at the right of the plot for tumours with the higher rCBV values
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Tumour rCBV was obtained from DSC-MRI (Fig. 1)b yt w o
independent observers. Bland and Altman plots revealed low
inter- and intraobserver variation (Fig. 2). The closest
observed limits of agreement were between the first observa-
tions of the neuroradiologist and neurosurgeon (mean −0.17,
range −1.27 to 0.93; Fig. 2a). The widest observed limits of
agreement were between the repeat observations of the neuro-
surgeon(mean0.08,range−1.59to1.95; Fig. 2c). The greatest
variation was observed in tumours with higher rCBV values.
Histopathology, genotype and rCBV
Oligodendroglial tumours of different histopathology sub-
types and grade did not have significantly different rCBV
measurements (Figure 3a,b). Loss of both 1p36 and 19q13
was seen in 6/9 grade II oligodendrogliomas, 6/14 grade II
oligoastrocytomas, 4/4 grade III oligodendrogliomas, and 3/
10 grade III oligoastrocytomas. Tumours with the −1p/−19q
genotype had significantly higher rCBV than those with
intact 1p and 19q (Fig. 3c). Similar findings were observed
when primary tumours only were analysed (data not
shown). ROC analysis was used to determine the specificity
and sensitivity of rCBV as a potential non-invasive tool to
distinguish oligodendroglial neoplasms with or without the
−1p/−19q genotype. The area under the ROC curve was
0.853 (95% confidence interval: 0.778–0.927). A cut-off
value of 1.59 for rCBV (sensitivity 92%, specificity 76%)
best discriminated oligodendroglial tumours with and
without the −1p/−19q genotype (Fig. 3c).
To facilitate comparison of rCBV with genotype and
clinicopathological characteristics (Table 1), tumours were
considered to have high rCBV if this was greater than 1.59
as determined by the ROC analysis (Fig. 4). High rCBV
values were significantly more common in tumours with loss
of 1p36 and 19q13 and less common in tumours with 17p13
loss and p53 mutation. Three tumours in the series had loss
of chromosome 10q22–26, of which two also had loss of
10p11–15; all had high rCBV. One tumour with high rCBV
had loss of 1p36 without loss of 19q13. As for numerical
data, there was no significant association between high
rCBVand histology subtype or grade. Contrast enhancement
was weakly associated with high rCBV in the series but not
in primary tumours. No associations were seen between
tumour rCBVand patient age <50 years versus age ≥50 years,
Fig. 3 Box plots of rCBV
against (a) histopathology
subtype (P=0.279*), (b) histo-
pathology grade (P=0.442*),
and (c) genotype (P=0.001*) in
oligodendroglial tumours. The
optimal rCBV cut-off that
distinguishes tumour genotype
is shown by the horizontal
line. *Student’s t-test
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associations between rCBV, genotype and clinicopathologi-
cal characteristics were obtained if only primary tumours
were analysed (Table 1).
rCBV and outcome following PCV chemotherapy
Of the 37 patients, 33 had PCV chemotherapy following
DSC-MRI (median 0.7 months, range 0.1–15.2 months), of
whom 26 with primary tumours received PCV chemother-
apy as the first oncology therapy, 6 with recurrent or
persistent disease treated initially with radiotherapy re-
ceived PCV as second oncology therapy, and 1 had PCV
following radiotherapy and temozolomide. One patient with
primary tumour had therapy switched to radiotherapy at the
end of the first cycle because of reaction to procarbazine.
The remainder received a median of four cycles of PCV
(range one to six). Response to therapy was assessed in 32
patients (Fig. 4). Measured radiological changes and
clinical factors permitted response assessment using stan-
dard criteria of Macdonald et al. [23] in all patients showing
enhancement. However, in tumours showing no enhance-
ment assessed using T2-weighted MR images, three
showed radiological change in cross-sectional area of
>25% to <50%, accompanied by clinical benefit; these
were included in the minor response (MR) category. None
of those showing enhancement had measured radiological
changeinthisrange.Response(i.e.complete,partialor minor;
seeFig.4 legend for definition) was seen in tumours with and
without high rCBV. Similarly, non-responders (i.e. patients
with stable or progressive disease) had either high or low
tumour rCBV (Table 1, Fig. 4). Response was strongly
associated with genotype; all 16 tumours with loss of 1p36
and 19q13 responded compared with 5 of 17 tumours with
intact 1p36/19q13 (Chi
2 P<0.001). Of the 16 responders in
the 1p36/19q13 loss group, 14 had high rCBV. The five
responders in the intact 1p36/19q13 group all had low rCBV
and the four tumours with high rCBV failed to respond.
The relationship between rCBV, genotype, histopathology
and survival following PCV in the series and in those with
Table 1 rCBV, molecular genetics and clinical characteristics in the series and primary tumours
All tumours Primary tumours
n Number of tumours with high
rCBV
P
value
a
n Number of tumours with high
rCBV
P
value
a
Loss of 1p36 and
19q13
Yes 19 17 (89%) 0.000* 16 14 (88%) 0.000
No 18 4 (22%) 14 2 (14%)
Loss of 17p13 Yes 11 2 (18%) 0.003* 8 0 (0%) 0.001
No 26 19 (73%) 22 16 (73%)
Loss of 10q 22–26 ±
10p11–15
Yes 3 3 (100%) 0.238 1 1 (100%) 1.0
no 33 17 (52%) 29 15 (52%)
p53 mutation(exon
5–8)
Yes 11 2 (18%) 0.004* 8 0 (0%) 0.001
No 25 18 (72%) 21 15 (71%)
Patient age (years) <50 25 13 (52%) 0.491 20 9 (45%) 0.260
>50 12 8 (67%) 10 7 (70%)
Histology subtype Oligodendroglioma 13 10 (77%) 0.091 11 8 (73%) 0.142
Oligoastrocytoma 24 11 (46%) 19 8 (42%)
WHO histology
grade
II 23 11 (48%) 0.191 9 9 (43%) 0.118
III 14 10 (71%) 21 7 (78%)
Contrast
enhancement
Absent 8 2 (25%) 0.046 8 2 (25%) 0.092
Present 28 19 (68%) 21 14 (68%)
Tumour location Temporal 14 7 (50%) 0.733 13 6 (46%) 0.713
Nontemporal 23 14 (61%) 17 10 (59%)
Tumour status Primary 30 16 (53%) 0.674
Recurrent 7 5 (71%)
Response to PCV
All tumours Responders 21 14 (67%) 0.142 17 11 (65%) 0.097
Nonresponders 11 4 (36%) 8 2 (25%)
Tumours with loss
of 1p/19q
Responders 16 14 (88%) 13 11 (85%)
Nonresponders 0 0
Tumours with intact
1p/19q
Responders 5 0 (0%) 0.245 4 0 (0%) 0.515
Nonresponders 11 4 (36%) 8 2 (25%)
aProbability calculated by Fisher’s Exact test. Responders showed complete, partial or minor response and non-responders had stable or
progressive disease.
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and low-grade pathology were associated with longer PFS
and OS. Histopathology subtype was not significantly
associated with outcome. Increased rCBV was only associ-
ated with short PFS and OS when adjusted for the −1p/−19q
genotype. Tumours with intact 1p/19q and high rCBV (two
grade III primary oligoastrocytoma, one grade II recurrent
oligodendroglioma, one grade III recurrent oligoastrocy-
toma) were associated with shorter PFS and OS than
tumours with intact 1p/19q and low rCBV or those with lp/
19q loss and high rCBV (Fig. 5a,b). Similar findings were
observed if primary tumour only were analysed (Fig. 5c,d).
Compared with significant clinicopathological parameters,
high rCBV was an independent prognostic factor for PFS
when adjusted for 1p/19q status (Cox regression: PFS:
hazard ratio 13.4, 95% CI 1.3–133; P=0.008) and for PFS
and OS in patients with intact 1p/19q (Cox regression: PFS:
hazard ratio 16.5, 95% CI 1.8–152.2; P=0.004; OS: hazard
ratio 7.4, 95% CI 1.6–33.3; P=0.013).
Discussion
To our knowledge this is the first study investigating the
relationship between rCBV, genotype and outcome in
oligodendroglial tumours treated with PCV chemotherapy.
The cohort was drawn from a larger series in an ongoing
prospective study of oligodendroglial neoplasms [15–18]
and reflects the range of patients given PCV chemotherapy
in routine clinical practice. Tumours with rCBV >1.59 were
more likely to have 1p/19q loss. PCV chemosensitivity was
predicted by 1p/19q loss, but high rCBV was not necessary
for response. Following chemotherapy, rCBV was signifi-
cantly associated with PFS and OS only after adjustment
for genotype.
DSC-MRI can be used to determine cerebral perfusion
parameters such as rCBV, relative cerebral blood flow and
permeability, but with the instrumentation available to us
was restricted to rCBV. As in other studies [8, 20, 25, 26],
placement of ROI in regions within tumour of greatest
Fig. 4 rCBV, molecular genetics and clinical characteristics. rCBV
for each tumour is given as the mean±standard deviation of three
independent observations. The arrow indicates tumours with rCBV
above (high rCBV) and below the cut-off value of 1.59 (low rCBV).
CR complete response (disappearance of all tumour, off steroids and
neurologically stable or improved), PR partial response (50% or
greater reduction in cross-sectional area, steroids stable or reduced,
and neurologically stable or improved); MR minor response (>25 to
<50% reduction in cross-sectional area, steroids stable or reduced, and
neurologically stable or improved); PD progressive disease (25% or
greater increase in cross-sectional area or any new tumour on CT/MR
images and/or neurologically worse with steroids stable or increased);
SD stable disease (all other situations); P primary tumour, R recurrent
tumour
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observer variability. The greatest variation was seen in
tumours with high rCBV, reflecting heterogeneity of blood
volume within these tumours. In this series, tumours with
the −1p/−19q genotype were more likely to have high
rCBV than those with intact 1p/19q. The ROC analysis
determined an optimal cut-off (rCBV >1.59) for predicting
the −1p/−19q genotype with 92% sensitivity and 76%
specificity. These data suggest that in conjunction with
histopathology, rCBV may be used to distinguish tumours
of the oligodendroglial lineage.
MRI studies of tumour vasculature in gliomas have
demonstrated that rCBV may be useful in the non-invasive
determination of tumour grade and vascularity [21, 25, 27,
28]. Compared to their low-grade counterparts, high-grade
tumours have elevated rCBV, associated with increased
mitotic activity [29]. rCBV correlates with conventional
angiographic assessment of tumour vascular density and
histological measures of angiogenesis such as microvascu-
lar density and VEGF expression [26, 30–32], which
reflects the histopathological finding of increasing neo-
vascularization with grade [19]. However, most studies
have investigated astrocytic gliomas or included a variety
of glioma pathologies and large series of oligodendroglial
neoplasms are uncommon. Recent reports suggest that
rCBV values in oligodendrogliomas render DSC-MRI-
based tumour grading inaccurate [28, 33], and rCBV may
be similar in low- and high-grade oligodendrogliomas [33].
Indeed low-grade oligodendrogliomas have significantly
elevated rCBV compared to low-grade astrocytomas [8]. In
our series, rCBV did not distinguish oligodendrogliomas
from oligoastrocytomas, nor was rCBV significantly dif-
ferent between grade II and III tumours. This lack of
correlation between rCBV and grade is consistent with the
increased microvessel density seen in both low- and high-
grade oligodendroglial tumours [34, 35].
It has been postulated that the tumour vasculature in
oligodendrogliomas contributes to their chemosensitivity
[12–14]. In an anaplastic oligodendroglioma treated with
PCV chemotherapy, post-therapy volume changes and
normalization of rCBV were more evident in regions of
the pretherapy tumour that showed high rCBV [13]. In the
present study, tumours with and without the −1p/−19q
genotype, and high or low rCBV showed response to
chemotherapy when assessed using conventional criteria
[1, 23]. These data indicate that rCBV measured through
DSC-MRI is not a key factor in determining PCV
chemosensitivity. These findings may reflect the limita-
tions of DSC-MRI associated with contrast recirculation
and disruption of the blood–brain barrier in tumours [8,
9]. Alternatively, chemosensitivity may be influenced
more by blood flow than by volume. Further studies to
measure additional parameters associated with vascular
perfusion, including blood flow and permeability are
essential to establish whether these factors contribute to
chemosensitivity.
Table 2 rCBV and survival in the series and in those with primary tumours. PFS and OS were calculated from start date of PCV (n number of
cases, nc not calculated, nr median survival not reached). Contrast enhancement (present vs absent), age (<50 vs ≥50 years), ECOG performance
status (0–1v s≥2) and gender (male vs female) were not significantly related to PFS or OS
n Progression-free survival (months) Overall survival (months)
Median (95%
CI)
P
value
a
P
value
b
Median (95%
CI)
P
value
a
P
value
b
All tumours Loss of 1p36 and
19q13
Yes 16 >56 (nr) 0.005 >56 (nr) 0.020
No 17 8 (0–21) >49 (nr)
Histopathology
subtype
Oligodendroglioma 11 >56 (nr) 0.055 0.187 >56 (nr) 0.113 0.288
Oligoastrocytoma 21 8 (9–41) 50 (9–91)
Histopathology
grade
II 19 >56 (nr) 0.004 0.002 >56 (nr) 0.007 0.012
III 14 4 (8–26) 21 (8–34)
rCBV Low 14 >46 (nr) 0.766 0.003 >49 (nr) 0.585 0.002
High 19 46 (nc) >56 (nr)
Primary
tumours
Loss of 1p36 and
19q13
Yes 14 >56 (nr) 0.037 >56 (nr) 0.056
No 12 >39 (nr) 49
Histopathology
subtype
Oligodendroglioma 10 >56 (nr) 0.055 0.137 All censored 0.092 0.209
Oligoastrocytoma 16 46 (6–86) 50 (6–101)
Histopathology
grade
II 17 >56 (nr) 0.047 0.009 >56 (nr) 0.048 0.041
III 9 6 (13–37) 50 (nc)
rCBV Low 12 >46 (nr) 0.681 0.007 >49 (nr) 0.611 0.003
High 14 >56 (nr) >56 (nr)
aProbability calculated by the Log-Rank test.
bProbability calculated by the Log-Rank test after adjustment for 1p/19q genotype.
Table 2 rCBV and survival in the series and in those with primary
tumours. PFS and OS were calculated from start date of PCV (n
number of cases, nc not calculated, nr median survival not reached).
Contrast enhancement (present vs absent), age (<50 vs ≥50 years),
ECOG performance status (0–1v s≥2) and gender (male vs female)
were not significantly related to PFS or OS
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longer PFS and OS [5] but the impact of tumour
vasculature on prognosis in oligodendrogliomas is confined
to a few histopathological [34, 36, 37] and imaging studies
[12]. Although our cohort is small, we have presented
preliminary data that the prognostic significance of rCBV
may differ in tumours with or without the −1p/−19q
genotype. 1p/19q loss and low-grade pathology were
associated with favourable PFS and OS following PCV. In
other studies of astrocytic gliomas [28] or mixed low-grade
gliomas [11], high rCBV predicted poor prognosis. In our
series, rCBV alone was an unreliable indicator of outcome,
showing prognostic significance only after stratification for
genotype, suggesting different effects for the two genetic
subgroups at the cut-off used to classify tumours with high
rCBV. With this cut-off, tumours with high rCBV and 1p/
19q loss were associated with longer survival than those
with high rCBV and intact 1p/19q. Unlike astrocytic
gliomas, high rCBV values do not necessarily indicate
aggressive biology associated with poor outcome in
oligodendroglial neoplasms with 1p/19q loss, suggestive
of differences in the baseline biology of these two genetic
subtypes. These preliminary data therefore indicate that
further investigation of the prognostic significance of rCBV
in molecular subtypes of glioma in a much larger series is
warranted.
Fig. 5 rCBV and outcome following PCV chemotherapy: a, b all
patients; c, d patients with primary tumour only; a, c progression-free
survival; b, d overall survival.① Patients with tumours with low
rCBV (<1.59) and loss of 1p36 and 19q13 (all n=2, primary n=2).②
Patients with tumours with high rCBV (>1.59) and loss of 1p36 and
19q13 (all n=15, primary n=12).③ Patients with tumours with low
rCBV (<1.59) with intact 1p36 and 19q13 (all n=12, primary n=10).④
Patients with tumours with high rCBV (>1.59) and intact 1p36 and
19q13 (all n=4, primary n=2)
Neuroradiology (2006) 48:703–713 711Conclusion
In conclusion, we have shown that high rCBV is more
likely in oligodendroglial tumours with the −1p/−19q
genotype and may be a useful aid to diagnosis; however,
rCBV does not predict chemosensitivity. Lack of correla-
tion with histopathology grade and the data suggesting that
the prognostic significance of rCBV may differ in patients
with or without the −1p/−19q genotype, indicates that
different interpretation of rCBV data may be necessary for
oligodendroglial compared with astrocytic gliomas. Further
study is essential to fully evaluate the role of DSC-MRI in
the non-invasive diagnosis and prediction of prognosis in
gliomas with an oligodendroglial phenotype.
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